Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

Developing non-statin-based small compounds to battle the global epidemic of hyperlipidemia remains challenging. Here, we report the discovery of DC371739, an indole-containing tetrahydroisoquinoline compound with promising lipid-lowering effects, both in vitro and in vivo, and with good tolerabilit...

Full description

Bibliographic Details
Main Authors: Chen, H. (Author), Chen, K. (Author), Ding, Y. (Author), Hou, W. (Author), Huang, H. (Author), Jiang, H. (Author), Li, F. (Author), Li, X. (Author), Liu, C. (Author), Liu, H. (Author), Qi, S. (Author), Wang, J. (Author), Wang, Y. (Author), Wu, C. (Author), Wu, D. (Author), Xi, C. (Author), Yan, C. (Author), Zhang, R. (Author), Zhao, J. (Author)
Format: Article
Language:English
Published: Cell Press 2022
Subjects:
ANGPTL3
atorvastatin
combination treatment
HNF-1α
hyperlipidemia
PCSK9
tetrahydroisoqinoline
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items